CheckMate-227 Regimen Safety Profile
CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC
Three-Year Update From the CheckMate 227 Clinical Trial for Advanced NSCLC
Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022
Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape
Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC
Recent Combination Approval: CheckMate-9LA Regimen
Perspectives on the CheckMate 9LA study
CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Optimizing Immunotherapy Combination Strategies for Metastatic NSCLC: From Evidence to Practice
Nontargeted Treatments for Lung Cancer | Third Annual National General Medical Oncology Summit
Checkmate 067 - combined nivolumab and ipilimumab
Lung ESMO 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Joshua Reuss
Winship Grand Rounds: January 20, 2021 - Timothy Chan, MD, PhD
Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early Stage NSCLC
FDA Approval of a Biosimilar, Priority Review in Epithelioid Sarcoma, and More
NIVOLUMAB / IPILIMUMAB APPROVED IN EUROPE FOR FRONTLINE UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA
Expert highlights: RCC immunotherapy at ESMO 2019 | Axel Merseburger
IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLC